JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

The Market Access for CNS Therapeutics Summit is the only dedicated forum focused on tackling the unique commercial and ...

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...